Antiviral composition comprising a sulfated polysaccharide

21 Pages·2013·1.71 MB·English

US 20120237572A1
(19) United States
(12) Patent Application Publication (10) Pub. No.: US 2012/0237572 A1
GRASSAUER et al. (43) Pub. Date: Sep. 20, 2012
(54) ANTIVIRAL COMPOSITION COMPRISING A Publication Classi?cation
SULFATED POLYSACCHARIDE (51) Int CL
A61K 31/737 2006.01
(75) Inventors: Andreas GRASSAUER, Vienna A611) 31/16 E2006_01;
(AT); Eva A61K 9/00 (2006.01)
PRIESCHL-GRASSAUER, A61P 11/06 (2006.01)
Vienna (AT) A61P 11/00 (2006.01)
A61P 31/14 (2006.01)
(73) Assignee: MARINOMED A611’ 11/08 (2006.01)
BIOTECHNOLOGIE GMBH, (52) US. Cl. ......................................... .. 424/400; 514/54
Vlenna (AT) (57) ABSTRACT
(21) App1_ NO; 13/483,716 The present invention provides for the use of iota- and/or
kappa-carrageenan for the manufacture of an ant1v1ral phar
- _ maceutical composition for the prophylaxis or treatment of a
(22) Flled' May 30’ 2012 pathological condition or disease caused by or associated
_ _ With an infection by a respiratory virus selected from the
Related U-s- APPhcatmn Data group consisting of orthomyxovirus, paramyxovirus, aden
- - - - ovirus and coronavirus, The present invention further pro
(63) 5;?t gzuaggln0 021223)2521olfiggbi2gg3égtihggggog; vides for the use of fucoidan, in particular of high molecular
006'910’On Au’ 22 2001831) ' Weight fucoidan, for the manufacture of an antiviral pharma
g' ’ ' ceutical composition for the prophylaxis or treatment of a
pathological condition or disease caused by or associated
(60) Provisional application No. 60/935,668, ?led onAug. With an infection by a respiratory virus selected from the
24, 2007. group consisting of orthomyxovirus and paramyxovirus.
Patent Application Publication Sep. 20, 2012 Sheet 1 0f 10 US 2012/0237572 A1
120'
100»
80~
60
40
20
O.1 1 10 25 50 100
uglml
Fig.1
100'
90'
80“
79'
60'
5G‘
40'
30'
20'
10'
150 360
uglml
Fig.2
Patent Application Publication Sep. 20, 2012 Sheet 2 0f 10 US 2012/0237572 A1
100 -
90 -
80 ~
70 -
so
so -
40
so
20 -
O
0 0,1 1 10 25
pglm!
Fig.3
120'
1 00'
BO
60.
40"
20'
183 400
gglml
Fig.4
Patent Application Publication Sep. 20, 2012 Sheet 3 0f 10 US 2012/0237572 A1
120_
100
so
20'
400
pglml
Fig.5A
100
70'
60'
400 4D
pglml
Fig.5B
Patent Application Publication Sep. 20, 2012 Sheet 4 0f 10 US 2012/0237572 A1
160-‘
140
120
400 40
pgfmi
Fig.6A
% 50
40
s0
20
10
400 40
ugfml
Patent Application Publication Sep. 20, 2012 Sheet 5 0f 10 US 2012/0237572 A1
5007
450
400
350"
390
250
pglml 200'
washing step
Fig.7’
90 ~
8D~
70
50‘
40~
30'
20'
10
0.4
gglml
Fig.8
Patent Application Publication Sep. 20, 2012 Sheet 6 0f 10 US 2012/0237572 A1
‘120 '
100 '
80'
20'
0 i I ' n
O 8 24 32 48 56 72
hours pas! infection
Fig.9
140 ~
120 I
109 '
% 6D -
40 ~
20v
Fig.10
Patent Application Publication Sep. 20, 2012 Sheet 7 0f 10 US 2012/0237572 A1
110"
90:
70
50'
30
10'
"10 . . . .
0.01 0.1 ‘I ‘TB 100
140 '
120 *
100 “
BO“
%
46
20"
400 133 44 15 V 4 1.3 0.4
pgfmi
Fig.1.?

Patent Application Publication Sep. 20, 2012 Sheet 9 0f 10 US 2012/0237572 A1
120
100
80
% 6O
20
4130 44.4
pgim!
Fig.15
100'
90
a0
70'
so
% 5o
40
so
20'
10»
400 133.8 4 4. 4 14.8 4 1.3 0.4
pglml
Fig.16